MedKoo Cat#: 341433 | Name: Xibornol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Xibornol is a biochemical.

Chemical Structure

Xibornol
Xibornol
CAS#13741-18-9

Theoretical Analysis

MedKoo Cat#: 341433

Name: Xibornol

CAS#: 13741-18-9

Chemical Formula: C18H26O

Exact Mass: 258.1984

Molecular Weight: 258.41

Elemental Analysis: C, 83.67; H, 10.14; O, 6.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Xibornol; CP-34; CP 34; CP34; Bactacine.
IUPAC/Chemical Name
3,4-Xylenol, 6-isobornyl- (8CI)
InChi Key
RNRHMQWZFJXKLZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3
SMILES Code
CC1=CC(O)=C(C2CC3CCC2(C)C3(C)C)C=C1C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 258.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zeh A, Planert M, Klima S, Hein W, Wohlrab D. The flexible Triac-Brace for conservative treatment of idiopathic scoliosis. An alternative treatment option? Acta Orthop Belg. 2008 Aug;74(4):512-21. PubMed PMID: 18811036. 2: Cirri M, Mura P, Mora PC. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm. 2007 Aug 1;340(1-2):84-91. Epub 2007 Mar 30. PubMed PMID: 17531411. 3: Cairella M. [Active drugs in diseases of the respiratory system]. Clin Ter. 1988 Jul 15;126(1):67-9. Italian. PubMed PMID: 2973962. 4: Fabbri A, Tacchella A, Belli ML. Activity of xibornol against Staphylococcus aureus. Chemioterapia. 1988 Apr;7(2):86-8. PubMed PMID: 3396117. 5: Fraschini F, Scaglione F, Maierna G, Savio G, Gattei G, Falchi M. Non-interference of xibornol on the theophylline blood levels. Int J Clin Pharmacol Res. 1988;8(1):43-6. PubMed PMID: 3366502. 6: Scaglione F, Trazzi R, Odero A, Sambataro G, Savio G, Ferrara F, Fraschini F. Xibornol: multiple dose pharmacokinetics and diffusion in lung, tonsillar tissue and laryngeal mucosa. Int J Clin Pharmacol Res. 1988;8(6):457-61. PubMed PMID: 3253223. 7: Combe J, Simonnet F, Simonnet G. [Action of xibornol on cell division and macromolecular synthesis of gram-positive bacterias]. Ann Pharm Fr. 1988;46(1):19-26. French. PubMed PMID: 3146238. 8: Borzani M, Varotto F, Garlaschi L, Scotti G, Savio G. [Evaluation of the eradicating capacity of xibornol in pediatric pharyngeal carriers of beta-hemolytic streptococci and study of the interaction between the drug and the chemiluminescent activity of PMN leukocytes]. Minerva Pediatr. 1987 Jun 30;39(11-12):555-9. Italian. PubMed PMID: 3627066. 9: De Mattia D, Santoro A, Grumo AR, Santoro N. [Xibornol in inflammatory involvement of the upper airways in childhood. A comparative clinical investigation]. Minerva Pediatr. 1986 Nov 15;38(21):1017-24. Italian. PubMed PMID: 3807837. 10: Capristo AF, Maiello N, Coppola T, Decimo F, Miraglia del Giudice M Jr, Antignani RG. [Clinical evaluation of a new antibacterial agent, xibornol, in the treatment of bacterial infections of the upper respiratory tract in childhood. Comparison with erythromycin]. Minerva Pediatr. 1986 Jun 30;38(11-12):503-10. Italian. PubMed PMID: 3526110. 11: Oggero R, Pugliaro G, Galvagno G, Frigerio M. [Antibacterial efficacy of a new chemotherapeutic agent in acute infections of the upper respiratory tract in childhood. Controlled clinical trial of xibornol and josamycin]. Minerva Pediatr. 1985 May 31;37(10):419-24. Italian. PubMed PMID: 3900675. 12: Morandini G, Finiguerra M, Bagno M. [Efficacy and tolerability of a new chemotherapeutic agent in the treatment of recurrent chronic bronchitis: xibornol]. Clin Ter. 1985 Feb 15;112(3):233-9. Italian. PubMed PMID: 4028638. 13: Olivieri D, Savio G, Del Donno M, Annicelli A, Tranfa CM. [Effects of xibornol on mucociliary clearance in patients with chronic bronchopathy in an acute phase]. Arch Monaldi. 1984 Jul-Aug;39(4):301-6. Italian. PubMed PMID: 6537755. 14: Olivieri D, Savio G, Giacomelli P, Montella R, Del Donno M. [Clinical evaluation of the therapeutic efficacy of xibornol in acute infections in chronic pulmonary diseases (controlled clinical study)]. Arch Monaldi. 1984 Jul-Aug;39(4):289-300. Italian. PubMed PMID: 6399668. 15: Zanon P, De Rose V, Bersani C, Caritinos P, Mazzocchi P. In vivo study of xibornol on phagocyte functions. Chemioterapia. 1984 Jun;3(3):156-8. PubMed PMID: 6529770. 16: Layes Molla A, Donald JF. A comparison of Bracen and co-trimoxazole in the treatment of acute respiratory tract infections in children. J Int Med Res. 1982;10(4):239-43. PubMed PMID: 6981532. 17: Donald JF, Layes Molla A. A comparison of Bracen and penicillin V in the treatment of acute respiratory tract infections in children. J Int Med Res. 1982;10(4):244-9. PubMed PMID: 6811347. 18: Donald JF, Layes Molla A. A comparison of Bracen and ampicillin in the treatment of acute respiratory tract infections in children. J Int Med Res. 1982;10(4):234-8. PubMed PMID: 6749577.